“And on the heels of libdalzi in 2024, and YES2GO in 2025, we are targeting four commercial launches this year.”

In context

“tations, and reflecting continuing competitive headwinds. Moving to clinical progress, following a very productive year in 2025, we have a catalyst-rich year ahead, including phase three updates from Island One and Two trials evaluating islatrovir plus lenacapavir, a potential first once-weekly oral treatment for people with virologically suppressed HIV. Two phase three updates for Trodelvy, including the EVOQUE-03 trial in metastatic non-small cell lung cancer, and the ASCENT GYN-01 trial in advanced endometrial cancer. Lastly, we expect an update on the phase three IDEAL study evaluating libdalzi in second-line primary biliary cholangitis with only incomplete response to UDCA. The strength and the pace of progress in our clinical pipeline is driving a steady cadence of product launches. And on the heels of libdalzi in 2024, and YES2GO in 2025, we are targeting four commercial launches this year. Including Trodelvy for first-line metastatic triple-negative breast cancer, extending beyond second-line treatment for which Trodelvy is a standard of care, following positive results from the phase three ASCENT-03 and ASCENT-04 studies. A new daily oral combination of bictegravir and lenacapavir for HIV treatment, following positive updates from the phase three ARTISTRY One and ARTISTRY Two trials, Anidocel, our potential best-in-disease BCMA CAR T, for fourth-line or later relapsed or refractory multiple myeloma, and bruleviratide in the US following approval in the EU for treatment of chronic hepatitis delta. These commercial and clinical milestones reflect the success of our diversification strategy that has been shaping Gilead Sciences, Inc. over the last six years. We have up to 10”